Cancer immunology and immunotherapy are driving forces of research and development in
oncology, mostly focusing on CD8+ T cells and the tumor microenvironment. Recent …

Recent advances in cancer immunotherapy—ranging from immune-checkpoint blockade
therapy to adoptive cellular therapy and vaccines—have revolutionized cancer treatment …

Cancer vaccines aim to direct the immune system to eradicate cancer cells. Here we review
the essential immunologic concepts underpinning natural immunity and highlight the …

Most clinically applied cancer immunotherapies rely on the ability of CD8+ cytolytic T cells to
directly recognize and kill tumour cells,–. These strategies are limited by the emergence of …

T cells mediate antigen-specific immune responses to disease through the specificity and
diversity of their clonotypic T cell receptors (TCRs). Determining the spatial distributions of T …

The T cell receptor (TCR) complex is a naturally occurring antigen sensor that detects,
amplifies and coordinates cellular immune responses to epitopes derived from cell surface …

The theory that cancer-associated fibroblasts (CAFs) are immunosuppressive cells has
prevailed throughout the past decade. However, recent high-throughput, high-resolution …

Immunosuppressive regulatory T cells (Tregs) provide a main mechanism of tumor immune
evasion. Targeting Tregs, especially in the tumor microenvironment (TME), continues to be …

T cells are at the center of cancer immunology because of their ability to recognize mutations
in tumor cells and directly mediate cancer cell killing. Immunotherapies to rejuvenate …

Neoadjuvant immunotherapies (NITs) have led to clinical benefits in several cancers.
Characterization of the molecular mechanisms underlying responses to NIT may lead to …